Yizun Medicine Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$13.9M
- Investors
-
14
Yizun Medicine General Information
Description
Developer of cell therapy designed for solid tumors. The company focuses on research and development on solid tumor treatment and allogeneic cells and is accelerating the development of allogeneic cell drugs for the treatment of advanced liver cancer, proving patients with innovative immune cell therapy technologies and products.
Contact Information
Website
www.stphibio.comCorporate Office
- Room 208, 2nd Floor, Building 1/2
- Number 658 Bin'an Road, Binjiang District
- Hangzhou, Zhejiang 310051
- China
Corporate Office
- Room 208, 2nd Floor, Building 1/2
- Number 658 Bin'an Road, Binjiang District
- Hangzhou, Zhejiang 310051
- China
Yizun Medicine Timeline
Yizun Medicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A1) | 15-Apr-2024 | $13.9M | Completed | Generating Revenue | ||
| 5. Secondary Transaction - Private | 28-Feb-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 05-Jan-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 05-Jun-2019 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 13-Apr-2018 | Completed | Startup |
Yizun Medicine Patents
Yizun Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026153328-A1 | Chimeric receptor complex based on transmembrane structure of nkg2d | Pending | 14-Jan-2025 | ||
| WO-2026002282-A1 | Nanobodies targeting and/or specifically binding to b7-h3 | Pending | 28-Jun-2024 | ||
| JP-2026531351-A | Modified cells and their use | Pending | 03-Aug-2023 | ||
| AU-2024318322-A1 | Modified cells and uses thereof | Pending | 03-Aug-2023 | ||
| EP-4754241-A1 | Modified cells and uses thereof | Pending | 03-Aug-2023 | C12N5/0636 |
Yizun Medicine Signals
Yizun Medicine Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hangzhou Hi-Tech Financial Investment Group | Venture Capital | Minority | ||
| Hangzhou Tailong Venture Capital Partnership | Growth/Expansion | Minority | ||
| TigerYeah Capital | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Shenzhen Chongshi Private Equity Investment Fund Management | PE/Buyout | Minority |
Yizun Medicine FAQs
-
When was Yizun Medicine founded?
Yizun Medicine was founded in 2018.
-
Where is Yizun Medicine headquartered?
Yizun Medicine is headquartered in Hangzhou, China.
-
What is the size of Yizun Medicine?
Yizun Medicine has 20 total employees.
-
What industry is Yizun Medicine in?
Yizun Medicine’s primary industry is Drug Discovery.
-
Is Yizun Medicine a private or public company?
Yizun Medicine is a Private company.
-
What is Yizun Medicine’s current revenue?
The current revenue for Yizun Medicine is .
-
How much funding has Yizun Medicine raised over time?
Yizun Medicine has raised $18.2M.
-
Who are Yizun Medicine’s investors?
Hangzhou Hi-Tech Financial Investment Group, Hangzhou Tailong Venture Capital Partnership, TigerYeah Capital, , and Shenzhen Chongshi Private Equity Investment Fund Management are 5 of 14 investors who have invested in Yizun Medicine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process